Arbios Systems files Chapter 11
This article was originally published in The Gray Sheet
Executive Summary
The maker of the Sepet liver assist device files for bankruptcy protection on Jan. 9, with plans to sell the company through a bid solicitation plan. In a phase I/II clinical trial, 11 out of 14 patients saw a reduction in hepatic encephalopathy. Last summer, Arbios acknowledged it would need to raise considerable capital to conduct the additional trials needed to launch the device in the U.S. and Europe (1"The Gray Sheet" June 9, 2008, p. 10). The company announced in August it had suspended all operations except fundraising efforts to support a Sepet launch or to enter into a strategic partnership
You may also be interested in...
Startups Persevere Toward Gaining Artificial Liver Approval
The potential market opportunity for an artificial liver keeps players in the game, even though many companies have tried and failed in the past
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.